Using a new stem-cell based drug screening technology with the potential to reinvent and greatly reduce the cost of the way new pharmaceuticals are developed, researchers have found a compound more effective in protecting the neurons killed in amyotrophic lateral sclerosis — Lou Gehrig’s disease — than two drugs that failed in human clinical trials after hundreds of millions of dollars had been invested in them.